The lack of clinical response in breast cancers treated with gefitinib in vivo has been partially attributed to activation of this pathway downstream of EGFR, or ineffective methods of identifying those tumors that show an EGFR-dependent signature. This evidence concerns the gene EGFR and breast carcinoma.